Management of metabolic syndrome: Statins

Endocrinology and Metabolism Clinics of North America

Volumn 33, Issue 3, 2004, Pages 509-523

  Xydakis, Antonios M ^a,b   Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X;

EID: 3242675815     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.03.011     Document Type: Review

References (81)

1. Reilly M.P., Rader D.J. The metabolic syndrome: more than the sum of its parts? Circulation. 108:2003;1546-1551
2. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359
3. Ford E.S., Giles W.H. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 26:2003;575-581
4. Lewis G.F., Carpentier A., Adeli K., Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 23:2002;201-229
5. Meigs J.B., Wilson P.W., Nathan D.M., D'Agostino R.B. Sr., Williams K., Haffner S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes. 52:2003;2160-2167
6. Lorenzo C., Okoloise M., Williams K., Stern M.P., Haffner S.M. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 26:2003;3153-3159
7. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689
8. Pyörälä M., Miettinen H., Laakso M., Pyörä lä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 98:1998;398-404
9. McGill H.C. Jr., McMahan C.A., Herderick E.E., Zieske A.W., Malcom G.T., Tracy R.E., et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 105:2002;2712-2718
10. Grundy S.M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 105:2002;2696-2698
11. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2002;2709-2716
12. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 25:2002;1129-1134
13. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 92:2003;18J-26J
14. Haffner S., Cassells H.B. Metabolic syndrome - a new risk factor of coronary heart disease? Diabetes Obes Metab. 5:2003;359-370
15. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344:2001;1343-1350
16. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
18. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 27:(Suppl 1):2004;S15-S35
19. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 88:2001;265-269
20. Lu W., Resnick H.E., Jablonski K.A., Jones K.L., Jain A.K., Howard W.J., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 26:2003;16-23
21. Williams K., Sniderman A.D., Sattar N., D'Agostino R. Jr., Wagenknecht L.E., Haffner S.M. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 108:2003;2312-2316
22. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620
23. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., et al., for the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 98:1998;2513-2519
24. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al., for the AFCAPS/TexCAPS research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622
25. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
26. Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al., for the Scandinavian Simvastatin Survival Study group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 159:1999;2661-2667
27. ALLHAT Officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 288:2002;2998-3007
28. Heart Protection Study collaborative group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 361:2003;2005-2016
29. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
30. Sever P.S., Dahlöf B., Poulter N., Wedel H., for the ASCOT steering committee and investigators. ASCOT-LLA: questions about the benefits of atorvastatin: authors' reply. Lancet. 36:2003;1986-1987
31. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 52:2003;1210-1214
32. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 139:2003;802-809
33. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 108:2003;414-419
34. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051
35. Pyörälä K., Ballantyne C., Lee M., Shah A., Maccubbin D., Gumbiner B., et al. Reduction of coronary events by simvastatin in non-diabetic coronary heart disease patients with and without metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). [abstract 81-OR] Diabetes. 52:(Suppl 1):2003;A19
36. Sacks F.M., Tonkin A.M., Craven T., Pfeffer M.A., Shepherd J., Keech A., et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 105:2002;1424-1428
37. Torres J.L., Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 18:2003;471-478
38. Ballantyne C.M., Hoogeveen R.C. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 146:2003;227-233
39. Sniderman A.D., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 135:2001;447-459
40. Ayyobi A.F., Brunzell J.D. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 92:2003;27J-33J
41. Mangaloglu L., Cheung R.C., Van Iderstine S.C., Taghibiglou C., Pontrelli L., Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism. 51:2002;409-418
42. Watts G.F., Chan D.C., Barrett P.H., O'Neill F.H., Thompson G.R. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord. 27:2003;862-865
43. Dane-Stewart C.A., Watts G.F., Pal S., Chan D., Thompson P., Hung J., et al. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 52:2003;1279-1286
44. Winkelmann B.R., Hoffmann M.M., Nauck M., Kumar A.M., Nandabalan K., Judson R.S., et al. Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J. 3:2003;284-296
45. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al., for the STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 92:2003;152-160
46. McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., Blasetto J.W. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 19:2003;689-698
47. Ballantyne C.M., Stein E.A., Paoletti R., Southworth H., Blasetto J.W. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 91:2003;25C-27C
48. Hunninghake D.B., Ballantyne C.M., Maccubbin D.L., Shah A.K., Gumbiner B., Mitchel Y.B. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 25:2003;1670-1686
49. Ballantyne C.M., Blazing M.A., Hunninghake D.B., Davidson M.H., Yuan Z., DeLucca P., et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 146:2003;862-869
50. Stein D.T., Devaraj S., Balis D., Adams-Huet B., Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 21:2001;2026-2031
51. Parhofer K.G., Barrett P.H., Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 85:2000;4224-4230
52. Pontrelli L., Parris W., Adeli K., Cheung R.C. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 51:2002;334-342
53. Blake G.J., Albert M.A., Rifai N., Ridker P.M. Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. Eur Heart J. 24:2003;1843-1847
54. Caslake M.J., Stewart G., Day S.P., Daly E., McTaggart F., Chapman M.J., et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis. 171:2003;245-253
55. Winkler K., Abletshauser C., Hoffmann M.M., Friedrich I., Baumstark M.W., Wieland H., et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 87:2002;5485-5490
56. McLaughlin T., Abbasi F., Lamendola C., Leary E., Reaven G.M. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme A reductase inhibitor treatment of combined dyslipidemia. Metabolism. 51:2002;1355-1359
57. Melenovsky V., Malik J., Wichterle D., Simek J., Pisarikova A., Skrha J., et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J. (144):2002;e6
58. Watts G.F., Barrett P.H., Ji J., Serone A.P., Chan D.C., Croft K.D., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 52:2003;803-811
59. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 25:2002;1198-1202
60. Vega G.L., Ma P.T., Cater N.B., Filipchuk N., Meguro S., Garcia-Garcia A.B., et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 91:2003;956-960
61. Fernandez-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 24:2003;278-301
62. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 112:2003;1785-1788
63. Festa A., Hanley A.J., Tracy R.P., D'Agostino R. Jr., Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 108:2003;1822-1830
64. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes. 52:2003;1799-1805
65. Festa A., D'Agostino R. Jr., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 51:2002;1131-1137
66. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 107:2003;391-397
67. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:2001;64-70
68. Costa A., Casamitjana R., Casals E., Alvarez L., Morales J., Masramon X., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 20:2003;743-745
69. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060
70. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 107:2003;2409-2415
71. März W., Winkler K., Nauck M., Böhm B.O., Winkelmann B.R. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health Study). Am J Cardiol. 92:2003;305-308
72. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 108:2003;2292-2297
73. Hsueh W.A., Quiñones M.J. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 92:2003;10J-17J
74. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 87:2002;563-568
75. van Venrooij F.V., van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., Banga J.D. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 25:2002;1211-1216
76. Sowers J.R. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol. 91:2003;14B-22B
77. McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 87:2002;1451-1458
78. Maison P., Mennen L., Sapinho D., Balkau B., Sigalas J., Chesnier M.C., et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis. 160:2002;155-160
79. Balk E.M., Lau J., Goudas L.C., Jordan H.S., Kupelnick B., Kim L.U., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 139:2003;670-682
80. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362
81. Stalenhoef A.F.H., Ballantyne C.M., Sarti C., Wilpshaar W., Southworth H. A comparative study with rosuvastatin in subjects with metabolic syndrome: rfationale and design of the COMETS study. [abstract 2559] Diab Metab. 29:(spec no 2):2003;4S318